Table 2

SIRs, familial proportions (% of affected cases with affected sibling), and PAFs for sibling history

Cancer siteICD-7/histologySIR95% CIOaProportion (%)PAF (%)
Oral140–1, 143–8, 1611.170.312.6040.220.03
Stomach1511.190.113.4040.340.05
Colorectal adenocarcinoma153–4/096 3.01 b 2.403.69911.851.23
Pancreas1571.690.164.8520.210.09
Lung162–3 2.55 1.833.37461.310.79
Breastc170 2.02 1.872.177275.652.85
Cervixc171 2.15 1.433.02301.070.57
Endometriumc172 3.30 2.114.75221.471.03
Ovaryc175 2.82 1.873.95301.350.87
Prostated177 3.72 2.605.03342.121.55
Testisd178 10.02 7.3813.05482.302.07
Kidney180 5.25 3.437.47281.200.97
Bladder181 1.84 1.052.85160.620.28
Melanoma190 3.03 2.543.561411.781.19
Skin1912.490.894.8760.400.24
Nervous system193 2.10 1.632.64660.810.43
Thyroid194 7.65 5.1610.64321.371.19
Endocrine195 3.84 2.625.28321.010.74
Non-Hodgkin’s lymphoma200, 202 2.61 1.733.67280.750.46
Hodgkin’s disease201 7.13 3.8811.35140.680.59
Leukemia204–9 3.53 2.305.01260.600.43
  • a O, observed cases with affected sibling.

  • b Bold type: 95% CI does not include 1.00.

  • c Families with ≥2 daughters.

  • d Families with ≥2 sons.